Clinical Trial Update: Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase Ib/II trial evaluating the addition of copanlisib to maintenance trastuzumab and pertuzumab after initial chemotherapy in advanced HER2-positive breast …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Copanlisib (copanlisib)
• HERCEPTIN (trastuzumab)
• Perjeta (pertuzumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-06-27